JP2023500391A5 - - Google Patents
Info
- Publication number
- JP2023500391A5 JP2023500391A5 JP2022526822A JP2022526822A JP2023500391A5 JP 2023500391 A5 JP2023500391 A5 JP 2023500391A5 JP 2022526822 A JP2022526822 A JP 2022526822A JP 2022526822 A JP2022526822 A JP 2022526822A JP 2023500391 A5 JP2023500391 A5 JP 2023500391A5
- Authority
- JP
- Japan
- Prior art keywords
- albumin
- mutation
- cancer
- composition
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962933820P | 2019-11-11 | 2019-11-11 | |
| US62/933,820 | 2019-11-11 | ||
| US202062991469P | 2020-03-18 | 2020-03-18 | |
| US62/991,469 | 2020-03-18 | ||
| PCT/US2020/060070 WO2021096997A1 (en) | 2019-11-11 | 2020-11-11 | Biomarkers for nanoparticle compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023500391A JP2023500391A (ja) | 2023-01-05 |
| JP2023500391A5 true JP2023500391A5 (https=) | 2023-11-20 |
Family
ID=75846208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022526822A Pending JP2023500391A (ja) | 2019-11-11 | 2020-11-11 | ナノ粒子組成物のためのバイオマーカー |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20230000844A1 (https=) |
| EP (1) | EP4058000A4 (https=) |
| JP (1) | JP2023500391A (https=) |
| KR (1) | KR20220113699A (https=) |
| CN (1) | CN114945358A (https=) |
| AU (1) | AU2020382817A1 (https=) |
| BR (1) | BR112022009018A2 (https=) |
| CA (1) | CA3161105A1 (https=) |
| IL (1) | IL292859A (https=) |
| MX (1) | MX2022005715A (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| ES3009356T3 (en) | 2015-06-29 | 2025-03-26 | Abraxis Bioscience Llc | Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors |
| IL277402B1 (en) | 2018-03-20 | 2026-04-01 | Abraxis Bioscience Llc | Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin |
| BR112022007710A2 (pt) | 2019-10-28 | 2022-07-12 | Abraxis Bioscience Llc | Composições farmacêuticas de albumina e rapamicina |
| WO2024228964A1 (en) * | 2023-04-30 | 2024-11-07 | Aadi Bioscience, Inc. | Treatments comprising an mtor inhibitor nanoparticle composition |
| WO2025129108A1 (en) | 2023-12-14 | 2025-06-19 | Aadi Bioscience, Inc. | Methods of treating a cancer in an individual |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2131821B1 (en) * | 2007-03-07 | 2018-05-09 | Abraxis BioScience, LLC | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| US20140186447A1 (en) * | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| WO2015170248A1 (en) * | 2014-05-05 | 2015-11-12 | Cellworks Research India Pvt. Ltd. | Combination of nelfinavir, metformin and rosuvastatin for treating cancer caused by aberrations in pten/tp53 |
| ES3009356T3 (en) * | 2015-06-29 | 2025-03-26 | Abraxis Bioscience Llc | Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors |
| JP2018521058A (ja) * | 2015-06-29 | 2018-08-02 | アブラクシス バイオサイエンス， エルエルシー | ナノ粒子ｍＴＯＲ阻害剤併用治療を使用して固形腫瘍を処置する方法 |
| KR20240144442A (ko) * | 2015-06-29 | 2024-10-02 | 아브락시스 바이오사이언스, 엘엘씨 | 나노입자 조성물에 대한 바이오마커 |
| EP3727368A4 (en) * | 2017-12-19 | 2021-10-20 | Abraxis BioScience, LLC | METHOD OF TREATMENT IN COLON CANCER WITH NANOPARTICLE MTOR INHIBITOR COMBINATION THERAPY |
-
2020
- 2020-11-11 EP EP20887933.8A patent/EP4058000A4/en active Pending
- 2020-11-11 AU AU2020382817A patent/AU2020382817A1/en not_active Abandoned
- 2020-11-11 JP JP2022526822A patent/JP2023500391A/ja active Pending
- 2020-11-11 US US17/775,562 patent/US20230000844A1/en not_active Abandoned
- 2020-11-11 IL IL292859A patent/IL292859A/en unknown
- 2020-11-11 KR KR1020227019284A patent/KR20220113699A/ko active Pending
- 2020-11-11 MX MX2022005715A patent/MX2022005715A/es unknown
- 2020-11-11 CA CA3161105A patent/CA3161105A1/en active Pending
- 2020-11-11 BR BR112022009018A patent/BR112022009018A2/pt unknown
- 2020-11-11 CN CN202080092690.1A patent/CN114945358A/zh active Pending
- 2020-12-02 US US17/110,133 patent/US20210137848A1/en not_active Abandoned
-
2022
- 2022-12-19 US US18/084,411 patent/US20230293449A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023500391A5 (https=) | ||
| JP2013523744A5 (https=) | ||
| Rahal et al. | Genomics of adult and pediatric solid tumors | |
| Jones et al. | Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer | |
| JP2015503613A5 (https=) | ||
| Jachowski et al. | Modern therapies of nonsmall cell lung cancer | |
| Wu et al. | Recent advances in ferrocene-based nanomedicines for enhanced chemodynamic therapy | |
| CN108778276A (zh) | 用于治疗flt3突变型增殖性疾患相关突变的克莱拉尼 | |
| CN110996927A (zh) | 复发性胶质母细胞瘤(rgbm)的治疗方法 | |
| Chuang et al. | Targeted therapies for the treatment of glioblastoma in adults | |
| Shen et al. | Ultrasound‐triggered cascade delivery via poly‐oxaliplatin nanoparticles for immunotherapy | |
| Han et al. | Supramolecular engineering of molecular inhibitors in an adaptive cytotoxic nanoparticle for synergistic cancer therapy | |
| Sukrithan et al. | Kinase inhibitors in thyroid cancers | |
| CN111565799A (zh) | 治疗神经内分泌肿瘤的方法 | |
| Jang et al. | Tumor microenvironment regulation by reactive oxygen species-mediated inflammasome activation: TME regulation by ROS-mediated inflammasome: J.-H. Jang et al. | |
| Coelho et al. | Radioresistance in rectal cancer: can nanoparticles turn the tide? | |
| JP2024063000A (ja) | 新規なクレノラニブの使用 | |
| Gao et al. | Theranostic nanoplatform based on polydopamine-coated magnetic mesoporous silicon for precise cancer triplex nanotherapy and multimodal imaging | |
| JP2021501203A5 (https=) | ||
| Pindiprolu et al. | Nanocarrier-mediated modulation of cGAS-STING signaling pathway to disrupt tumor microenvironment | |
| Seol et al. | A pilot prospective study of refractory solid tumor patients for NGS-based targeted anticancer therapy | |
| Li et al. | Advancement of regulating cellular signaling pathways in NSCLC target therapy via nanodrug | |
| Wang et al. | Perspectives of metal-organic framework nanosystem to overcome tumor drug resistance | |
| Chen et al. | New strategies to enhance the efficacy of PD-1/PD-L1 inhibitors in treating microsatellite stable colorectal cancer | |
| Kim et al. | Multicenter nonrandomized trial of ramosetron versus palonosetron in controlling chemotherapy-induced nausea and vomiting for colorectal cancer |